DE69831745D1 - Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen - Google Patents

Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen

Info

Publication number
DE69831745D1
DE69831745D1 DE69831745T DE69831745T DE69831745D1 DE 69831745 D1 DE69831745 D1 DE 69831745D1 DE 69831745 T DE69831745 T DE 69831745T DE 69831745 T DE69831745 T DE 69831745T DE 69831745 D1 DE69831745 D1 DE 69831745D1
Authority
DE
Germany
Prior art keywords
treatment
growth hormone
insulin resistance
promoting substances
hormone promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69831745T
Other languages
English (en)
Other versions
DE69831745T2 (de
Inventor
Philip Albert Carpino
Charles Kwok-Fung Chiu
Bruce Allen Lefker
Lydia Codetta Pan
Judith Lee Treadway
Michael Paul Zawistoski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE69831745D1 publication Critical patent/DE69831745D1/de
Publication of DE69831745T2 publication Critical patent/DE69831745T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69831745T 1997-06-25 1998-06-05 Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen Expired - Fee Related DE69831745T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
US50790P 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (2)

Publication Number Publication Date
DE69831745D1 true DE69831745D1 (de) 2006-02-09
DE69831745T2 DE69831745T2 (de) 2006-08-31

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69831745T Expired - Fee Related DE69831745T2 (de) 1997-06-25 1998-06-05 Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen

Country Status (40)

Country Link
US (3) US6448263B1 (de)
EP (1) EP1000085B1 (de)
JP (2) JP2000514099A (de)
KR (1) KR20010014224A (de)
CN (2) CN1530107A (de)
AP (1) AP1145A (de)
AR (1) AR012256A1 (de)
AT (1) ATE305477T1 (de)
AU (1) AU747510B2 (de)
BG (1) BG104008A (de)
BR (1) BR9810477A (de)
CA (1) CA2294464A1 (de)
CO (1) CO4950621A1 (de)
DE (1) DE69831745T2 (de)
DZ (1) DZ2539A1 (de)
EA (1) EA002089B1 (de)
EG (1) EG21712A (de)
ES (1) ES2248899T3 (de)
HN (1) HN1998000088A (de)
HR (1) HRP980361A2 (de)
HU (1) HUP0001922A3 (de)
ID (1) ID24345A (de)
IL (7) IL154111A0 (de)
IN (1) IN189724B (de)
IS (1) IS5275A (de)
MA (1) MA24581A1 (de)
NO (1) NO996205D0 (de)
NZ (1) NZ500655A (de)
OA (1) OA11242A (de)
PA (1) PA8452601A1 (de)
PE (1) PE105399A1 (de)
PL (1) PL337659A1 (de)
SK (1) SK175699A3 (de)
TN (1) TNSN98113A1 (de)
TR (1) TR199903257T2 (de)
TW (1) TW553943B (de)
UA (1) UA64751C2 (de)
WO (1) WO1998058949A1 (de)
YU (1) YU70199A (de)
ZA (1) ZA985546B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (de) * 2000-03-09 2004-03-03 Pfizer Products Inc. Metaboliten von Hexahydropyrazolo[4,3-c]pyridinen
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
PL1828480T3 (pl) * 2004-12-21 2014-10-31 Solenis Tech Cayman Lp Reaktywne żywice kationowe do zastosowania jako czynniki wzmacniające na sucho i na mokro w układach wytwarzania papieru zawierających jony siarczynowe
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2118080B1 (de) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Makrocyclische ghrelin-rezeptormodulatoren und verwendungsverfahren dafür
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
RU2670978C9 (ru) * 2013-05-28 2018-11-22 Раквалиа Фарма Инк. Полиморфные формы
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3131916B1 (de) * 2014-08-05 2018-11-14 RaQualia Pharma Inc. Serinderivate als ghrelin-rezeptoragonisten
CN106795158A (zh) * 2014-10-31 2017-05-31 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的四氢吡唑并吡啶衍生物
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN120265641A (zh) * 2023-04-21 2025-07-04 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3190802A (en) 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
AU676525B2 (en) 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
RO115804B1 (ro) 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
CZ134296A3 (en) 1993-11-09 1996-12-11 Merck & Co Inc Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (de) * 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
DE69637855D1 (de) 1995-12-22 2009-04-16 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1998058947A1 (en) * 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
ZA985546B (en) 2000-01-10
IL154114A0 (en) 2003-07-31
BR9810477A (pt) 2007-05-22
TW553943B (en) 2003-09-21
IL154115A0 (en) 2003-07-31
WO1998058949A1 (en) 1998-12-30
IL154111A0 (en) 2003-07-31
HRP980361A2 (en) 1999-02-28
AU747510B2 (en) 2002-05-16
SK175699A3 (en) 2001-04-09
EG21712A (en) 2002-02-27
JP3742643B2 (ja) 2006-02-08
NZ500655A (en) 2002-02-01
PA8452601A1 (es) 2000-05-24
DE69831745T2 (de) 2006-08-31
US6630487B2 (en) 2003-10-07
US6867202B1 (en) 2005-03-15
IL156465A (en) 2004-07-25
EA199901075A1 (ru) 2000-08-28
CN1259140A (zh) 2000-07-05
CN1152049C (zh) 2004-06-02
IN189724B (de) 2003-04-19
PL337659A1 (en) 2000-08-28
AR012256A1 (es) 2000-09-27
TR199903257T2 (xx) 2000-12-21
EP1000085A1 (de) 2000-05-17
BG104008A (en) 2000-07-31
JP2000514099A (ja) 2000-10-24
AP1145A (en) 2003-02-14
AU7445698A (en) 1999-01-04
CO4950621A1 (es) 2000-09-01
NO996205L (no) 1999-12-15
ATE305477T1 (de) 2005-10-15
PE105399A1 (es) 1999-11-04
DZ2539A1 (fr) 2003-02-08
TNSN98113A1 (fr) 2005-03-15
EA002089B1 (ru) 2001-12-24
JP2005097261A (ja) 2005-04-14
OA11242A (en) 2003-07-23
IS5275A (is) 1999-11-26
HUP0001922A3 (en) 2001-02-28
EP1000085B1 (de) 2005-09-28
IL156465A0 (en) 2004-01-04
CN1530107A (zh) 2004-09-22
ES2248899T3 (es) 2006-03-16
NO996205D0 (no) 1999-12-15
CA2294464A1 (en) 1998-12-30
KR20010014224A (ko) 2001-02-26
MA24581A1 (fr) 1998-12-31
US20030100561A1 (en) 2003-05-29
HK1028051A1 (en) 2001-02-02
YU70199A (sh) 2003-01-31
UA64751C2 (uk) 2004-03-15
HN1998000088A (es) 1999-01-08
IL154116A0 (en) 2003-07-31
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
US6448263B1 (en) 2002-09-10
ID24345A (id) 2000-07-13
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
ATE305477T1 (de) Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen
DE69720243D1 (de) Chemische modifikation von biomedizinischen materialien mit genipin
DE69836640D1 (de) Vorrichtung zur behandlung von gewebe mit mehrfach-elektroden
DE69817446D1 (de) Behandlung von diabetes
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
DE69731736D1 (de) Injektionsbehandlung zur beherrschung von muskelkrämpfen und damit einhergehenden schmerzen
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
DE69830591D1 (de) HEILUNG VON BRUCHVERLETZUNGEN UNTER VERWENDUNG VON PTHrP ANALOGEN
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE355840T1 (de) Behandlung der diabetes mit thiazolidindione und metformin
DE69821520D1 (de) Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz
DE60043305D1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
DE69327891D1 (de) Material zur Entfernung von pathogener Substanz und mit diesem Material hergestellter Blutfilter
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69826045D1 (de) Multi-Ort Herzschrittmacher zur Behandlung von Herzinsuffizienzen mit Reizimpulsen
ATE305790T1 (de) Behandlung der diabetes mit thiazolidindione, insulin sekretionförderer und biguanide
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
NO975718D0 (no) Behandling av insulinresistens
ATE258062T1 (de) Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee